The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain on track for the first quarter and the third quarter of CY2026, respectively SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announ ...

CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:30 AM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or ...

MANCHESTER, United Kingdom, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Smartkem, Inc. (Nasdaq: SMTK), (“Smartkem” or the “Company”), a leader in advanced materials, today announced that it has entered into a debt conversion agreement, pursuant to which certain outstanding accounts payable of Smartkem were satisfied in full through the issuance of equity securities of the Company. Under the terms of the agreement, approximately $2.0 million of outstanding obligations owed were converted into a combination of shares o ...

NEW ALBANY, Ohio, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Abercrombie & Fitch Co. (NYSE: ANF) will host its quarterly earnings conference call for all interested parties on Wednesday, March 4, 2026, at 8:30 a.m. ET. A press release detailing the company’s fourth quarter and full year results is expected to be issued shortly after 7:30 a.m. ET. In addition, a presentation of the fourth quarter and full year results will be available on the company’s website at approximately 7:30 a.m. ET. Conference Call:To access ...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (Nasdaq: MLCI) (“Mount Logan” or the “Company”) announced today the final results of its offer to purchase for cash up to $15 million of its shares of common stock, $0.001 par value, at a fixed price of $9.43 per share (the “Tender Offer”). The Tender Offer expired at 5:00 p.m., New York City time, on February 2, 2026 (the “Expiration Time”). The Tender Offer was oversubscribed. In accordance with the terms and conditions of the Tender Off ...

Core Viewpoint - Clearmind Medicine Inc. has entered into a development agreement with Polyrizon Ltd. to enhance the bioavailability and clinical advancement of its lead compound MEAI for addiction-related and other CNS disorders [1][2][3] Group 1: Collaboration Details - The agreement involves the application of Polyrizon's proprietary intranasal hydrogel technology to develop an optimized formulation of Clearmind's MEAI [2][3] - The collaboration aims to leverage the advantages of intranasal delivery for CNS-targeted therapeutics, which include enhanced nasal residence time, targeted delivery, and bypassing first-pass metabolism [3][5] Group 2: Company Insights - Clearmind is focused on discovering and developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including addiction and mental health disorders [1][6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [6] Group 3: Technology Overview - Polyrizon specializes in developing innovative medical device hydrogels for nasal delivery, which can provide a barrier against viruses and allergens [7] - Their proprietary Capture and Contain™ hydrogel technology aims to improve bioadhesion and retention at the nasal deposition site for drug delivery [7]

Core Viewpoint - Polyrizon Ltd. has entered into a development agreement with Clearmind Medicine Inc. to leverage Polyrizon's intranasal delivery platform for the clinical development of Clearmind's drug candidate MEAI, aimed at treating addiction-related and other CNS conditions [1][2][3] Group 1: Collaboration Details - The collaboration aims to advance an intranasal formulation of MEAI to support Clearmind's future clinical development programs [2] - Polyrizon's proprietary intranasal technology is designed to enable targeted and efficient delivery of drugs, potentially offering significant value in Clearmind's clinical pathway [3] Group 2: Polyrizon's Technology - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The company's Capture and Contain TM hydrogel technology is designed to enhance bioadhesion and prolong retention at the nasal site for drug delivery [4][6] Group 3: Clearmind's Focus - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address underserved health issues, including alcohol use disorder [7] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [8]

Core Viewpoint - Jeffs' Brands Ltd is expanding into the global homeland security sector through its subsidiary KeepZone AI Inc, which has signed an exclusive reseller agreement with DSIT Solutions Ltd to introduce advanced underwater security solutions in Mexico [1][2][4]. Group 1: Company Overview - Jeffs' Brands is a data-driven e-commerce company that has recently pivoted into the homeland security market, leveraging its expertise in data-driven operations [5]. - KeepZone AI Inc. is a wholly-owned subsidiary of Jeffs' Brands focused on advanced AI-driven solutions for homeland security [1][5]. Group 2: Strategic Partnership - KeepZone will facilitate DSIT's entry into the Mexican market to combat underwater drug smuggling and protect offshore assets [2][4]. - The partnership aims to support national authorities and critical infrastructure operators by providing advanced underwater security technologies [3][4]. Group 3: Market Context - Drug trafficking organizations are increasingly utilizing underwater methods to evade detection, prompting a need for enhanced maritime security solutions [3]. - DSIT's advanced underwater security systems are designed to detect and respond to covert underwater activities, addressing a critical gap exploited by organized criminal networks [3][4]. Group 4: Security Solutions Offered - The solutions to be introduced include detection of hostile divers, identification of unmanned underwater vehicles, protection of ports and coastal assets, and support for maritime drug intervention operations [9][10].

Core Viewpoint - Cambridge Acquisition Corp. has successfully priced its initial public offering (IPO) of 20,000,000 units at $10.00 per unit, with each unit comprising one Class A ordinary share and one-third of a redeemable warrant [1]. Group 1: IPO Details - The IPO consists of 20,000,000 units priced at $10.00 each, with each unit including one Class A ordinary share and one-third of a redeemable warrant [1]. - Each whole warrant allows the holder to purchase one Class A ordinary share at a price of $11.50 [1]. - The units are expected to begin trading on the Nasdaq under the ticker symbol "CAQUU" starting February 6, 2026 [1]. Group 2: Underwriting and Closing - BTIG, LLC is serving as the sole book-running manager for the offering [2]. - The underwriter has a 45-day option to purchase an additional 3,000,000 units at the IPO price to cover over-allotments [2]. - The offering is anticipated to close on February 9, 2026, subject to customary closing conditions [2]. Group 3: Company Overview - Cambridge Acquisition Corp. is a special purpose acquisition company (SPAC) designed to engage in mergers, amalgamations, share exchanges, asset acquisitions, or similar business combinations with one or more businesses [5].

Core Insights - SAGA Metals Corp. is strategically positioned to benefit from the U.S. government's "Project Vault," which aims to enhance domestic supply chains for critical minerals, particularly titanium, in alignment with national security priorities [1][3][4] Group 1: Project Vault and U.S. Strategic Initiatives - Project Vault establishes the U.S. Strategic Critical Minerals Reserve as a public-private partnership to store essential raw materials across U.S. facilities [2] - The Export-Import Bank of the United States (EXIM) has approved a Direct Loan of up to USD 10 billion to support Project Vault, aimed at strengthening U.S. production and processing capacity [3] - The initiative is part of a broader strategy by the Trump administration to counter China's dominance in critical minerals, particularly in refining [4] Group 2: Titanium's Strategic Importance - Titanium is recognized as a critical mineral for defense and aerospace applications due to its strength-to-weight ratio and corrosion resistance [11] - Over 90% of mined titanium is processed into pigment, highlighting a significant supply chain gap for aerospace-grade titanium [12] - The defense sector consumes a substantial portion of titanium, with some aircraft, like the F-15, comprising up to 40% titanium by weight [13] Group 3: SAGA Metals' Project Focus - SAGA's flagship Radar Ti-V-Fe Project in Labrador has achieved a 100% drilling success rate in 2025, with exceptional grades of titanium, vanadium, and iron [13] - The project is strategically located near existing infrastructure, enhancing its potential for supporting secure supply chains for defense and aerospace [14] - The evolving policy environment emphasizes the importance of North American critical minerals projects, reinforcing SAGA's focus on supply-chain security and advanced manufacturing [14] Group 4: Implications of Project Vault - SAGA Metals identifies key implications from Project Vault, including the rising strategic value of titanium and other critical metals in defense readiness and aerospace manufacturing [17] - There is potential for increased investment in North American exploration and processing capacity as governments prioritize secure supply [17] - Enhanced public-private cooperation is expected to create resilient supply chains and mitigate market disruption risks [17]